$5.3 M

Trimedyne Revenue FY, 2015
Trimedyne Revenue growth (FY, 2014 - FY, 2015), %(2%)
Trimedyne Gross profit (FY, 2015)1.8 M
Trimedyne Gross profit margin (FY, 2015), %33.4%
Trimedyne Net income (FY, 2015)-595 K
Trimedyne EBIT (FY, 2015)-543 K
Trimedyne Cash, 30-Sept-2015365 K

Trimedyne Revenue

Trimedyne revenue was $5.33 m in FY, 2015 which is a 2.3% year over year decrease from the previous period.

Embed Graph

Trimedyne Funding

Summary Metrics

Founding Date

1980

Trimedyne Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015

Revenue

6.0m5.5m5.3m

Revenue growth, %

(9%)(2%)

Cost of goods sold

3.6m3.5m3.6m

Gross profit

2.4m1.9m1.8m

Gross profit Margin, %

40%36%33%

R&D expense

407.0k471.0k420.0k

General and administrative expense

2.3m1.9m1.9m

Operating expense total

2.7m2.4m2.3m

EBIT

(368.0k)(466.0k)(543.0k)

EBIT margin, %

(6%)(9%)(10%)

Interest expense

10.0k7.0k

Interest income

2.0k

Pre tax profit

(578.0k)

Income tax expense

17.0k7.0k17.0k

Net Income

329.0k(381.0k)(595.0k)

Trimedyne Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015

Cash

1.6m1.3m365.0k

Inventories

1.2m1.6m1.8m

Current Assets

3.4m3.5m2.7m

PP&E

706.0k635.0k480.0k

Goodwill

544.0k544.0k544.0k

Total Assets

4.7m4.7m3.8m

Accounts Payable

177.0k278.0k138.0k

Current Liabilities

703.0k1.1m716.0k

Long-term debt

43.0k4.0k

Additional Paid-in Capital

51.3m51.3m51.4m

Retained Earnings

(46.8m)(47.2m)(47.8m)

Total Equity

4.0m3.6m3.1m

Financial Leverage

1.2 x1.3 x1.2 x

Trimedyne Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015

Net Income

329.0k(381.0k)(595.0k)

Depreciation and Amortization

241.0k218.0k190.0k

Accounts Receivable

18.0k12.0k47.0k

Inventories

646.0k(380.0k)(227.0k)

Accounts Payable

28.0k101.0k(140.0k)

Cash From Operating Activities

1.4m(103.0k)(773.0k)

Purchases of PP&E

(188.0k)(28.0k)(35.0k)

Cash From Investing Activities

(188.0k)(28.0k)(35.0k)

Cash From Financing Activities

(146.0k)(149.0k)(119.0k)

Interest Paid

2.0k10.0k7.0k

Income Taxes Paid

11.0k12.0k9.0k

Trimedyne Ratios

USDY, 2015

Financial Leverage

1.2 x